Noble

Noble is excited to attend and display at this year’s HFES conference in New Orleans March 20-23. Connect with us at booth 7 during the conference to chat about our Human Factors + offering for clients as well as our robust patient training and onboarding solutions.

As are getting ready to hit the market in droves in the next few years, the EU, particularly Norway according to this analysis, has demonstrated successful strategies for making these biosimilars available to patients while also realizing monetary savings. Learn more:

Norway 'excellent example' of how to increase access to biosimilars The European Union, and specifically Norway, has demonstrated successful strategies for making biosimilars available for patients — and realizing “tremendous savings” — that should be adopted in the United States, according to an analysis. “With exception of the Kaiser...

In 2019, became the fourth to be approved by the US FDA. Today, Organon touches on the importance of speed to market for the product.

Organon CEO pins high hopes on upcoming Humira biosimilar launch What’s in store for Merck spinout Organon’s second year? | What’s in store for Merck spinout Organon’s second year? Growth ambitions for birth control implant Nexplanon, plus tuned up sales expectations for its biosimilars and fertility businesses.

The Covid-19 pandemic has accelerated the digital transformation already underway in healthcare. As patient expectations around ease of access expand, the future of patient onboarding is turning digital.

The future patient onboarding process is digital Attar Naderi, UK Business Manager at Laserfiche describes the benefits of implementing a digital process for patient onboarding

Interesting conversations were had at the recent conference in Orlando. Check out talks around — from opportunities to hurdles — from the “CEOs Unplugged” session.

Biosimilars CEOs: Opportunities Abound, but Regulatory, “Branding” Hurdles Remain There remains risk in the US market due to regulatory and legal hurdles—not to mention a combative political environment, according to executives who gathered last week during the “CEOs Unplugged” session at Access! 2022, held by the Association for Accessible Medicines (AAM) in Orlando.

Did you know Noble offers full-service in-house design, photography and videography services for clients? Introducing our very own Noble Studios, a one-stop-shop for all your digital and visual needs including step-by-step training videos… right from our Orlando offices.

Noble is Excited to Announce Expansion of Service Offerings for Clients with the Addition of Noble Studios - Noble When Noble broke into the training device market many years ago, we quickly realized how much work there was to be done to help pharma partners achieve their goals for... Read More »

While patents on many are set to expire in the coming years, and are set to hit the market as a result, a panel discussed reasons for the slow adoption of biosimilars in the US market.

Panelists Explore What Exactly Is Holding Up US Adoption of Biosimilars Payer intervention, lack of patient savings, and confusion surrounding interchangeability are some of the many barriers standing in the way of US biosimilar uptake, with our group of panelists calling for big changes.

Why do we at Noble devote ourselves to supporting patients who self-administer drug therapies at home? Because research and studies show us they need more support:

Need for Patient and HCP Training - Noble Considerable Gaps Exist in Patient Training and Preparedness for Self-Injected Biologics and Self-Administered Nasal Therapies Millions of patients around the world rely heavily on self-injectable biologics and self-administered nasal therapies to... Read More »

Noble is looking to fill three positions in its Orlando headquarters. Please take a look and feel free to share with anyone you think would be interested. https://www.gonoble.com/careers/

Noble penned a piece in Drug Delivery News shedding light on the ongoing need for around to reduce negative transfer and other gaps for patients.

Noble can help patients reduce errors when self-administering biosimilar therapies - Drug Delivery Business Noble can help patients reduce errors when self-administering biosimilar therapies - Drug Delivery Business

Ford Motor Company recently shared the success it had converting 100% of health maintenance organization utilizers of brand drug Remicade (infliximab) to the Inflectra "with no disruption to patients and no negative feedback from its members."

Michigan Trade Group Outlines Best Practices for Biosimilar Adoption Ford Motor saved $5 million by switching patients to 5 biosimilars, and other manufacturers and employers in Michigan have achieved good results with switching programs, the Economic Alliance of Michigan reports.

Concerned about patient access to monoclonal antibody medications, like , patient groups in India appealed to the country’s executive administration to spur reforms in regulation. http://ow.ly/CtGG50HIe5q